<GlossaryTerm id="CDR0000367409"><TermName>iodine I 131-tositumomab</TermName><TermPronunciation>(I-oh-dine ... TAH-sih-TOO-moh-mab)</TermPronunciation><TermDefinition><DefinitionText>A drug used with another drug to treat certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the treatment of other types of cancer. Iodine I 131-tositumomab is a form of the monoclonal antibody tositumomab that is linked to the radioactive substance iodine I 131. It is a type of radioimmunoconjugate.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000711446" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;iodine I 131 tositumomab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000711447" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;yodo I 131-tositumomab&quot;" language="es" id="_4"/><SpanishTermName>yodo I 131-tositumomab</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa con otro medicamento para tratar ciertos tipos de linfoma no Hodgkin de células B. También está en estudio para tratar otros tipos de cáncer. El yodo I 131-tositumomab es una forma del anticuerpo monoclonal tositumomab que se une a la sustancia radiactiva yodo I 131. Es un tipo de radioinmunoconjugado.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2004-04-23</DateFirstPublished><DateLastModified>2017-03-23</DateLastModified></GlossaryTerm>
